XML 33 R19.htm IDEA: XBRL DOCUMENT
v3.22.1

Warrants | 3 Months Ended
--- | ---
Mar. 31, 2022
Warrants [Abstract] |
WARRANTS | NOTE 13: WARRANTS A summary of outstanding warrants is included below:
|  | Warrants (Equity) |
|  | Amount |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life |
Balance January 1, 2022 |  |  | 4,103,211 |  |  | $ | 4.48 |  |  |  | 1.73 |
Warrants issued |  |  | 5,851,505 |  |  |  | 1.535 |  |  |  | 5.00 |
Warrants exercised |  |  | (5,851,505 | ) |  |  | 1.535 |  |  |  | 4.86 |
Balance March 31, 2022 |  |  | 4,103,211 |  |  | $ | 4.15 |  |  |  | 1.48 |
|  | Warrants (Liability) |
|  | Amount |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life |
Balance January 1, 2022 |  |  | - |  |  | $ | - |  |  |  | - |
Warrants issued |  |  | 13,761,000 |  |  |  | 1.63 |  |  |  | 5.00 |
Warrants expired |  |  | - |  |  |  | - |  |  |  | - |
Balance March 31, 2022 |  |  | 13,761,000 |  |  | $ | 1.63 |  |  |  | 4.86 |
On February 17, 2022, in connection with obtaining a waiver of certain restrictions in investment documents between an investor and the Company in order to consummate the financing contemplated by the Credit Agreement, the Company paid consideration to such investor in the form of a warrant (the “Purchaser Warrant”) to purchase 1,400,000 shares of Company common stock in an at-the-market offering under Nasdaq rules. The number of shares of Company common stock subject to the Purchaser Warrant is equal to the waiver fee ($175) divided by $0.125 per share. The exercise price of the Purchaser Warrant is $1.41 per share, and the Purchaser Warrant is not exercisable until August 17, 2022. The Purchaser Warrant expires five years from the date of issuance. The Company evaluated the Purchaser Warrant and concluded that it does not meet the criteria to be classified within stockholders’ equity. The Purchaser Warrant includes provisions which could result in a different settlement value, for the Purchaser Warrant depending on the registration status of the underlying shares. Because these conditions are not an input into the pricing of a fixed-for-fixed option on the Company’s ordinary shares, the Purchaser Warrant is not considered to be indexed to the Company’s own stock. The Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations at each reporting date. At the date of issuance, the Company performed a Black-Scholes valuation of the Purchaser Warrant, resulting in a fair value of $0.8656 per warrant. In recording the warrant liability, the Company recorded an expense in the Condensed Consolidated Statement of Operations associated with the issuance of the Purchaser Warrant of $1,211. At March 31, 2022, the Company reassessed the fair value of the Purchase Warrant via Black Scholes valuation methodology and determined that the fair value of the Purchaser Warrant was $0.5815 per warrant, resulting in the Company recording a gain on the fair value of the Purchaser Warrant of $398 in the Condensed Consolidated Statement of Operations for the three months ended March 31, 2022. On February 3, 2022, the Company, entered into a Securities Purchase Agreement with a purchaser (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a private placement priced at-the-market under Nasdaq rules, (i) 1,315,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and accompanying warrants to purchase an aggregate of 1,315,000 shares of Common Stock, and (ii) pre-funded warrants to purchase up to an aggregate of 5,851,505 shares of Common Stock (the “Pre-Funded Warrants”) and accompanying warrants to purchase an aggregate of 5,851,505 shares of Common Stock (collectively, the “Private Placement”). The accompanying warrants to purchase Common Stock are referred to herein collectively as the “Common Stock Warrants.” Under the Securities Purchase Agreement, each Share and accompanying warrants to purchase Common Stock were sold together at a combined price of $1.535, and each Pre-Funded Warrant and accompanying warrants to purchase Common Stock were sold together at a combined price of $1.5349, for gross proceeds of approximately $11,000, before deducting placement agent fees and estimated offering expenses payable by the Company. During the three months ended March 31, 2022, each of the Pre-Funded Warrants were exercised. The Common Stock Warrants expire five years from the date of issuance, The Company evaluated the Pre-Funded Warrants and concluded that they met the criteria to be classified within stockholders’ equity, with proceeds recorded as common stock and additional paid-in-capital. The Company evaluated the Common Stock Warrant and concluded they do not meet the criteria to be classified within stockholders’ equity. The Common Stock Warrant include provisions which could result in a different settlement value, for the Common Stock Warrant depending on the registration status of the underlying shares. Because these conditions are not an input into the pricing of a fixed-for-fixed option on the Company’s ordinary shares, the Common Stock Warrant is not considered to be indexed to the Company’s own stock. The Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations at each reporting date. At the date of issuance, the Company performed a Black-Scholes valuation of the warrants, resulting in a fair value of $1.0927 per warrant. At March 31, 2022, the Company reassessed the fair value of these warrants via Black Scholes valuation methodology and determined that the fair value of these warrants was $0.5815 per warrant, resulting in the Company recording a gain on the fair value of these warrants of $3,664 in the Condensed Consolidated Statement of Operations for the three months ended March 31, 2022. On February 17, 2022, in connection with the restructured Credit Agreement with Slipstream, the Company issued 5,194,495 warrants with an exercise price of $2.00 per share which expire five years from the date of issuance (the “Lender Warrant”). These warrants are not exercisable until 180 days after the issuance date. The common shares underlying these warrants have not yet been registered for resale under the Securities Act of 1933, which provides Slipstream with an option for cashless exercise once the warrant becomes exercisable until such time as such registration occurs. The warrants issued to Slipstream expire five years from the date of issuance. The Company evaluated the Lender Warrant and concluded that it does not meet the criteria to be classified within stockholders’ equity. The Lender Warrant includes provisions which could result in a different settlement value, for the Lender Warrant depending on the registration status of the underlying shares. Because these conditions are not an input into the pricing of a fixed-for-fixed option on the Company’s ordinary shares, the Lender Warrant is not considered to be indexed to the Company’s own stock. The Company recorded these warrants as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations at each reporting date. At the date of issuance, the Company performed a Black-Scholes valuation of the warrants, resulting in a fair value of $0.8129 per warrant. In recording the warrant liability, the Company recorded an increased in debt discount in the Condensed Consolidated Balance Sheet associated with the issuance of the warrants of $4,223, which is being amortized through interest expense in the Condensed Consolidated Statement of Operations over the life of the Acquisition and Consolidation Term Loans. At March 31, 2022, the Company reassessed the fair value of these warrants via Black Scholes valuation methodology and determined that the fair value of these warrants was $0.5420 per warrant, resulting in the Company recording a gain on the fair value of these warrants of $1,408 in the Condensed Consolidated Statement of Operations for the three months ended March 31, 2022. As of March 31, 2022, there remained outstanding 597,678 warrants which contain weighted average anti-dilution protection. During the three months ended March 31, 2022, those warrants were subject to a downward adjustment in their strike price following completion of the Company’s issuance of common stock and warrants in (1) the Merger, (2) the Debt Offering, and (3) the Equity Offering – each in February 2022. The strike prices prior to adjustment ranged from $5.61 and $5.76 and were adjusted to between $3.41 and $3.48. The remaining weighted-average contractual life of warrants subject to weighted average anti-dilution protection is 0.67 years as of March 31, 2022. The repricing resulted in a reclassification of $31 between retained earnings and additional paid in capital during the three months ended March 31, 2022.

X
- References No definition available. + Details
Name: | crex_WarrantsAbstract
Namespace Prefix: | crex_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | crex_WarrantsTextBlock
Namespace Prefix: | crex_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration